[1] Jay, N. (2000) Cardiac Remodelling—Concepts and Clinical Implications: A Consensus Paper from an International Forum on Cardiac Remodelling. JAAC, 45, 582-596.
[2] Packer, M., Carver, J.R., Rhodeheffer, R.J., et al. (1991) Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure. The New England Journal of Medicine, 325, 1468-1475.
http://dx.doi.org/10.1056/NEJM199111213252103
[3] Digitalis Investigation Group (1997) The Effects of Digoxin on Mortality and Morbidity in Patients with Heart Failure. The New England Journal of Medicine, 336, 525-533.
http://dx.doi.org/10.1056/NEJM199702203360801
[4] Massie, B.M., Fisher, S.G., Deedwania, P.C., Singh, B.N., Fletcher, R.D. and Singh, S.N., for the CHF-STAT Investigators (1996) Effect of Amiodarone on Clinical Status and Left Ventricular Function in Patients with Congestive Heart Failure. Circulation, 93, 2128-2134.
http://dx.doi.org/10.1161/01.CIR.93.12.2128
[5] Pieske, B. (2004) Reverse Remodelling in Heart Failure—Fact or Fiction? European Heart Journal Supplements, 6, D66-D78.
http://dx.doi.org/10.1016/j.ehjsup.2004.05.019
[6] Fletcher, P. (2000) Cardiovascular Medicines, John Hunter Hospital, Newcastle: Beta Blockers in Heart Failure. Australian Prescriber, 23, No 6.
[7] Hobbs, F.D.R. (2000) Management of Heart Failure: Evidence versus Practice. Does Current Prescribing Provide Optimal Treatment for Heart Failure Patients? British Journal of General Practice, 50, 735-742.
[8] Brophy, J.M., Joseph, L. and Rouleau, J.L. (2001) Beta Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. Annals of Internal Medicine, 134, 550-560.
http://dx.doi.org/10.7326/0003-4819-134-7-200104030-00008
[9] Dobre, D., De Jongste, M.J., Lucas, C., Cleuren, G., van Veldhuisen, D.J., Ranchor, A.V. and Haaijer-Ruskamp, F. (2007) Effectiveness of Beta Blocker Therapy in Daily Practice Patients with Advanced Chronic Heart Failure: Is There an Effect-Modification by Age? British Journal of Clinical Pharmacology, 63, 356-364.
http://dx.doi.org/10.1111/j.1365-2125.2006.02769.x
[10] McMurray, J.J., et al. (2012) ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 33, 1787-1847.
[11] Eichhorn, E.J. and Bristow, M.R. (1996) Medical Therapy Can Improve the Biological Properties of the Chronically Failing Heart: A New Era in the Treatment of Heart Failure. Circulation, 94, 2285-2296.
[12] Shibata, M.C., Flather, M.D. and Wang, D.L. (2001) Systematic Review of the Impact of Beta Blockers on Mortality and Hospital Admissions in Heart Failure. European Journal of Heart Failure, 3, 351-357.
http://dx.doi.org/10.1016/S1388-9842(01)00144-1
[13] Ntusi, N.B. and Mayosi, B.M. (2009) Epidemiology of Heart Failure in Sub-Saharan Africa. Expert Review of Cardiovascular Therapy, 7, 169-180.
[14] Hobbs, F.D., Jones, M.I., Allan, T.F., Wilson, S. and Tobias, R. (2000) European Survey of Primary Care Physician Perceptions on Heart Failure Diagnosis and Management. European Heart Journal, 21, 1877-1887.
http://dx.doi.org/10.1053/euhj.2000.2170
[15] Magula, N.P. and Mayosi, B.M. (2003) Cardiac Involvement in HIV-Infected People Living in Africa: A Review. Cardiovascular Journal of Southern Africa, 14, 231-237.
[16] Berry, C., Murdoch, D.R. and McMurray, J.J.V. (2001) Economics of Chronic Heart Failure. European Journal of Heart Failure, 3, 283-291.
http://dx.doi.org/10.1016/S1388-9842(01)00123-4
[17] Yilmaz, M.B., Refiker, M., Guray, Y., Guray, U., Altay, H., Dermirkan, B., Caldir, V. and Korkmaz, S. (2007) Prescribing Patterns in Patients with Systolic Heart Failure at Hospital Discharge: Why Beta Blockers Are Under-Prescribed or Prescribed at Low Dose in Real Life. International Journal of Clinical Practice, 61, 225-230.
http://dx.doi.org/10.1111/j.1742-1241.2006.01157.x
[18] Krum, H. (1999) Beta Blockers in Heart Failure. The “New Wave” of Clinical Trials. Drugs, 58, 203-210.
http://dx.doi.org/10.2165/00003495-199958020-00001
[19] Stewart, S., Wilkinson, D., Hansen, C., Vaghela, V., Mvungi, R., McMurray, J. and Sliwa, K. (2008) Predominance of Heart Failure in the Heart of Soweto Study Cohort. Emerging Challenges for Urban African Communities. Journal of American Heart Association, 118, 2360-2367.
http://dx.doi.org/10.1161/circulationaha.108.786244
[20] Yancy, C.W., Fowler, M.B., Colucci, W.S., Gilbert, E.M., Bristow, M.R., Cohn, J.N., Lukas, M.A., Young, S.T. and Parker, M. (2001) Race and Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure. New England Journal of Medicine, 334, 1358-1365.
http://dx.doi.org/10.1056/NEJM200105033441803
[21] NICE5 Guidelines, CG5. Chronic Heart Failure; Management of Chronic Heart Failure in Adults in Primary and Secondary Care, July 2003.
www.nice.org.uk/guidance/cg5
[22] Haas, S.J., Vos, T., Gilbert, R.E. and Krum, H. (2003) Are Beta Blockers as Efficacious in Patients with Diabetes Mellitus as in Patients without Diabetes Mellitus Who Have Chronic Heart Failure? A Meta-Analysis of Large-Scale Clinical Trials. American Heart Journal, 146, 848-853.
http://dx.doi.org/10.1016/S0002-8703(03)00403-4
[23] Fuat, A., Hungin, A.P.S. and Murphy, J.J. (2003) Barriers to Accurate Diagnosis and Effective Management of Heart Failure in Primary Care: Qualitative Study. BMJ, 326, 196.
http://dx.doi.org/10.1136/bmj.326.7382.196